Crossmark

Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease

Crossref DOI link: https://doi.org/10.1007/s00277-025-06432-9

Published Online: 2025-05-30

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, En-Min

Tang, Yongmin

Liao, Chan

Lin, Shupeng

Shen, Heping

Wang, Di

Xu, Liyao

Zhang, Ping

Song, Hua

Xu, Xiaojun

Zhang, Jingying

Liang, Juan

Shen, Diying

Zhao, Fenying

Xu, Weiqun
Funding

Funding for this research was provided by:

Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province ((JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904, (JBZX-201904)
License Information

Text and Data Mining valid from 2025-05-30

Version of Record valid from 2025-05-30
More Information

Article History

Received: 31 March 2025

Accepted: 23 May 2025

First Online: 30 May 2025

Declarations

:

: Written informed consent was obtained from each patient’s parent for their clinical information to be used for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below